|
Thursday, March 26, 2020 |
|
AIM ImmunoTech(AIM)宣布進一步加大臨床試驗力度,評估安普利近作為當前新冠肺炎流行病的潛在保護性和早期療法的療效 |
AIM ImmunoTech(NYSE-American交易代碼: AIM)今天宣布,它正在積極尋找研究人員和地點進行安普利近的臨床測試,測試其作為由SARS-CoV-2新型冠狀病毒引發的新型肺炎的保護性預防和早期療法的療效。 more info >> |
|
AIM ImmunoTech(AIM)宣布进一步加大临床试验力度,评估安普利近作为当前新冠肺炎流行病的潜在保护性和早期疗法的疗效 |
AIM ImmunoTech(NYSE-American交易代码: AIM)今天宣布,它正在积极寻找研究人员和地点进行安普利近的临床测试,测试其作为由SARS-CoV-2新型冠状病毒引发的新型肺炎的保护性预防和早期疗法的疗效。 more info >> |
|
Tuesday, March 10, 2020 |
|
AIM ImmunoTech公司的藥物安普利近即將接受日本國立傳染病研究所的測試,作為引發人類新發傳染病——新型冠狀病毒肺炎(COVID-19)的新型SARS冠狀病毒(SARS-CoV-2)潛在治療藥物 |
專注於研發治療免疫疾病,病毒性疾病和多種癌症療法的免疫藥物公司AIM ImmunoTech(紐約證券交易所股票代碼:AIM)今天宣布,日本國立傳染病研究所(NIID)將開始測試AIM的藥物安普利近(Ampligen),以作為SAV-CoV-2引起的新型冠狀病毒感染性疾病——新型冠狀病毒肺炎的潛在治療藥物。實驗項目將在NIID和東京大學進行。 more info >> |
|
AIM ImmunoTech公司的药物安普利近即将接受日本国立传染病研究所的测试,作为引发人类新发传染病——新型冠状病毒肺炎(COVID-19)的新型SARS冠状病毒(SARS-CoV-2)潜在治疗药物 |
专注于研发治疗免疫疾病,病毒性疾病和多种癌症疗法的免疫药物公司AIM ImmunoTech(纽约证券交易所股票代码:AIM)今天宣布,日本国立传染病研究所(NIID)将 开始测试AIM的药物安普利近(Ampligen),以作为SAV-CoV-2引起的新型冠状病毒感染性疾病——新型冠状病毒肺炎的潜在治疗药物。 实验项目将在NIID和东京大学进行。 more info >> |
|
Friday, February 28, 2020 |
|
AIM ImmunoTech joins with ChinaGoAbroad for Ampligen China Entry against COVID-19 |
AIM ImmunoTech (NYSE American: AIM, or the Company) today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions. more info >> |
|
Thursday, February 27, 2020 |
|
AIM ImmunoTech joins with ChinaGoAbroad for Ampligen China Entry against COVID-19 |
AIM ImmunoTech (NYSE American: AIM, or the Company) today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions. more info >> |
|
AIM ImmunoTech(AIM)與中國走出去網站攜手推動安普利近引入中國,對抗新型冠狀病毒肺炎 |
專注於研發治療免疫疾病、病毒性疾病和多種癌症治療的免疫藥物公司AIM ImmunoTech(NYSE-American交易代碼: AIM,以下簡稱公司)今天宣布,公司已攜手中國走出去網站(CGA), 共同促進AIM的實驗藥物安普利近(Ampligen)引入中華人民共和國,用作針對新型冠狀病毒肺炎(COVID-19)的預防或早發治療藥物。 more info >> |
|
AIM ImmunoTech(AIM)与中国走出去网站携手推动安普利近引入中国,对抗新型冠状病毒肺炎 |
专注于研发治疗免疫疾病、病毒性疾病和多种癌症治疗的免疫药物公司AIM ImmunoTech(NYSE-American交易代码: AIM,以下简称公司)今天宣布,公司已携手中国走出去网站(CGA), 共同促进AIM的实验药物安普利近(Ampligen)引入中华人民共和国,用作针对新型冠状病毒肺炎(COVID-19)的预防或早发治疗药物。这种新型的SARS样冠状病毒流行病目前已有燎原之势。 more info >> |
|
Tuesday, February 18, 2020 |
|
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Coronavirus Epidemic |
AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. more info >> |
|
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic |
AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. more info >> |
|
|
|